Extended Data Fig. 9: CBD-IL-12 armoured CAR-T cells eradicates RM9-hSTEAP1 tumour in combination with CPI.
(a) Experimental timeline. Male C57BL6/J mice received subcutaneous injection of RM9-hSTEAP1 (5×105) on day 0. Mice were left untreated or treated with combination immunotherapies of CAR-T cells and CPIs. 5 million CAR+T cells were intravenously administered on day 4. 100 µg of Anti-PD-1 antibody was administered intraperitoneally on days 7, 11 and 15. 100 µg of anti-CTLA-4 antibody was administered on days 7 and 11. (b) Tumour volumes were measured (Untreated, UTD and hSTEAP1-mBBζ, n = 5; hSTEAP1-mBBζ + NFAT-IL-12 and hSTEAP1-mBBζ + NFAT-CBD-IL-12, n = 4. mean ± s.e.m.). (c) Individual tumour growth curves. (d) Survival rates. CR, complete response. (e) Body weight changes normalized to the body weights on day 0 (mean ± s.e.m.). (f) Serum IFNγ concentrations on day 10. The boxes extend from 25th to 75th percentiles, the center lines show median values and the whiskers extend to the minima and maxima. Statistical analyses were performed using (d) log-rank (Mantel-Cox) test or (f) Kruskal-Wallis test followed by Dunn’s multiple comparison (non-parametric data). P values are shown in figures.
